Research programme: autoimmune disorder therapies - Five Prime Therapeutics
Alternative Names: FP-069; FP-1069; FPA-126; FPT 025; FPT-1069; IL-34; Interleukin-34Latest Information Update: 02 Oct 2021
At a glance
- Originator Five Prime Therapeutics
- Class Recombinant proteins
- Mechanism of Action Cytokine receptor antagonists; Monocyte stimulants; Natural killer cell stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Autoimmune disorders
Highest Development Phases
- No development reported Autoimmune disorders; Inflammation; Respiratory tract disorders
- Discontinued Bacterial infections; Cancer
Most Recent Events
- 16 Apr 2021 Five Prime Therapeutics has been acquired by Amgen
- 16 Jul 2016 No recent reports of development identified for preclinical development in Autoimmune-disorders in USA (Parenteral)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Inflammation in USA (Parenteral)